The goal of this study was to test the hypothesis that antioxidant estrogen
s, by a mechanism independent of the estrogen receptor, protect phospholipi
ds residing in the plasma membrane of vascular smooth muscle cells from per
oxidation and peroxidation-induced cell growth and migration. Peroxidation
of membrane phospholipids was assessed by HPLC analysis of phospholipids ex
tracted from rat aortic vascular smooth muscle cells prelabeled with cis-pa
rinaric acid (a fatty acid that is susceptible to peroxidation, which quenc
hes its fluorescent properties). Incubation of cells for 2 hours with the p
eroxyl radical donor 2,2'-azobis-2,4-dimethylvaleronitrile (AMVN) caused pe
roxidation of all measured membrane phospholipids. This effect was attenuat
ed by pretreating cells for 15 minutes with 50 to 5000 ng/mL of 2-hydroxyes
tradiol (strong antioxidant but weak estrogen-receptor ligand) or 4-hydroxy
tamoxifen (strong antioxidant and potent estrogen-receptor ligand), but not
by estrone or droloxifene (both weak antioxidants but potent estrogen-rece
ptor ligands). Moreover, pretreatment of cells for 20 hours with physiologi
cal concentrations (0.3 ng/mL) of 2-hydroxyestradiol or pharmacologically r
elevant concentrations of 4-hydroxytamoxifen (40 ng/mL) also decreased AMVN
-induced phospholipid peroxidation, Both 2-hydroxyestradiol and 4-hydroxyta
moxifen were as effective as 2,2,5,7,8-pentamethyl-6-hydrochromane (an anti
oxidant homolog of vitamin E) in attenuating AMVN-induced peroxidation of m
embrane phospholipids. Also, physiological concentrations of 2-hydroxyestra
diol, but not estrone, and pharmacologically relevant concentrations of 4-h
ydroxytamoxifen attenuated AMVM-induced DNA synthesis, cell proliferation,
and cell migration. These studies demonstrate in vascular smooth muscle cel
ls that antioxidant estrogens via a non-estrogen receptor-dependent mechani
sm attenuate peroxidation of membrane phospholipids and peroxidation-induce
d cell growth and migration.